Johnson & Johnson, US4781601046

Johnson & Johnson stock: Ollin deal, EUR 248.88, down 1.02%

Published on 11/19/2026 at 07:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Johnson & Johnson agreed to acquire Ollin Biosciences, expanding its late-stage eye-disease pipeline. On Xetra, the stock closed at EUR 251.45 on Wednesday, November 18, 2026.

Deal Adds A New Pipeline Asset

  • Johnson & Johnson agreed to acquire Ollin Biosciences for EUR 2.2 billion upfront, with up to about EUR 1.13 billion in potential milestone payments.
  • The transaction would add a late-stage eye-disease drug candidate, with closing expected before the end of 2026.
Johnson & Johnson, US4781601046, Illustration mit AI erstellt.

Johnson & Johnson stock traded at 248.88 euros on Lang & Schwarz at 07:45 CET on Thursday, November 19, 2026, 1.02 percent below the Xetra close of Wednesday, November 18, 2026, at 251.45 euros.

The premarket move comes after Johnson & Johnson agreed to acquire Texas-based Ollin Biosciences. According to Reuters, the company will pay EUR 2.2 billion upfront and could owe up to about EUR 1.13 billion in regulatory and commercial milestone payments.

Ollin was established to develop treatments for vision-threatening diseases. Its lead asset is a late-stage candidate aimed at eye diseases, giving Johnson & Johnson another potential addition to its pharmaceutical pipeline. The transaction is expected to close before the end of 2026.

For investors, the deal increases exposure to future product development while adding execution and regulatory milestones ahead of a potential closing. The stock's premarket indication remains below the latest Xetra close as investors assess the acquisition alongside broader market conditions.

The S&P 500 provides the broader US equity-market backdrop for Johnson & Johnson stock.

More news and analyses on Johnson & Johnson stock

Disclaimer...
en | US4781601046 | JOHNSON & JOHNSON | boerse | 70534292 | bgmi